key: cord-0963626-o26rfxw4
authors: Ray, Arunima; Debata, Ipsita; Agrawal, Ishan; Panda, Maitreyee
title: COVID 19 and Immunosuppressants : an opinion pool of practising dermatologists of India
date: 2020-07-22
journal: Dermatol Ther
DOI: 10.1111/dth.14036
sha: 6b124058f096e57644425d9064edcb343389e5b0
doc_id: 963626
cord_uid: o26rfxw4

nan

This article is protected by copyright. All rights reserved.

Among the small molecules, Apremilast is more commonly used in India, compared to JAK inhibitors like Tofacitinib. Apremilast does not target specific cytokines, has no increased risk of infection, or reactivation of latent infections. A short t 1/2 makes it easier to stop and restart within a few days. Other than psoriasis, off-label uses include alopecia, apthous stomatitis, lichen planus and behcet's disease.

Limited immunosuppression makes them a safer therapeutic choice. 3 A reported case of psoriasis on Apremilast contracted COVID-19 and didnot develop any serious symptoms. 4 Only 32% of respondents would switch to smaller molecules depending on the case, 47.45% chose topical medications. Biologics, with a longer t½, are not easy to stop and do not have a broad immunosuppressive effect due to specific targets. Nevertheless, a monoclonal antibody like Rituximab, targeting B-cells, can be a cause for concern during a viral outbreak. Biologics trials in psoriasis demonstrated an increased infection risk with most TNFα blockers except Etanercept. 5 This article is protected by copyright. All rights reserved. 

IADVL position statement and recommendations on post lockdown dermatology practice amidst the Covid -19 pandemic (IADVL Academy and IADVL Executive Committee). Indian Dermatol Online J

COVID-19 and Immunomodulator/Immunosuppressant Use in

Apremilast in psoriasis and beyond: Big hopes on a small molecule

Apremilast as a potential treatment option for COVID -19: No symptoms of infection in a psoriatic patient

Should Biologics for Psoriasis Be Interrupted in the Era of COVID-19?

COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action

COVID-19 and psoriasis: Should we fear for patients treated with biologics?

Anti-tumor necrosis factor therapy and influenza: Keeping it in perspective